Vassilis I. Zannis - Publications

Affiliations: 
Boston University, Boston, MA, United States 
Area:
Biochemistry

149 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Dalakoura-Karagkouni K, Tiniakou I, Zannis VI, Kardassis D. Using adenovirus-mediated gene transfer to study the effect of myeloperoxidase on plasma lipid levels, HDL structure and functionality in mice expressing human apoA-I forms. Biochemical and Biophysical Research Communications. 622: 108-114. PMID 35843089 DOI: 10.1016/j.bbrc.2022.07.001  0.82
2021 Valanti EK, Dalakoura-Karagkouni K, Fotakis P, Vafiadaki E, Mantzoros CS, Chroni A, Zannis V, Kardassis D, Sanoudou D. Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK. Metabolism: Clinical and Experimental. 127: 154954. PMID 34875308 DOI: 10.1016/j.metabol.2021.154954  0.77
2018 Theofilatos D, Fotakis P, Valanti E, Sanoudou D, Zannis V, Kardassis D. HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway. Metabolism: Clinical and Experimental. 87: 36-47. PMID 29928895 DOI: 10.1016/j.metabol.2018.06.002  0.767
2018 Dafnis I, Raftopoulou C, Mountaki C, Megalou E, Zannis VI, Chroni A. ApoE isoforms and carboxyl-terminal truncated apoE4 forms affect neuronal BACE1 levels and Aβ production independently of their cholesterol efflux capacity. The Biochemical Journal. PMID 29743204 DOI: 10.1042/Bcj20180068  0.455
2018 Theofilatos D, Fotakis P, Valanti E, Sanoudou D, Zannis V, Kardassis D. HDL induces the expression of angiopoietin like 4 (ANGPTL4) gene in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway Atherosclerosis. 275. DOI: 10.1016/J.Atherosclerosis.2018.06.092  0.347
2017 Zannis VI, Su S, Fotakis P. Role of apolipoproteins, ABCA1 and LCAT in the biogenesis of normal and aberrant high density lipoproteins. Journal of Biomedical Research. PMID 29109329 DOI: 10.7555/JBR.31.20160082  0.433
2017 Daminelli EN, Fotakis P, Mesquita CH, Maranhão RC, Zannis VI. Tissue Uptake Mechanisms Involved in the Clearance of Non-Protein Nanoparticles that Mimic LDL Composition: A Study with Knockout and Transgenic Mice. Lipids. PMID 29094255 DOI: 10.1007/s11745-017-4306-6  0.341
2015 Tamehiro N, Park MH, Hawxhurst V, Nagpal K, Adams ME, Zannis VI, Golenbock DT, Fitzgerald ML. LXR Agonism Upregulates the Macrophage ABCA1/Syntrophin Protein Complex That Can Bind ApoA-I and Stabilized ABCA1 Protein, but Complex Loss Does Not Inhibit Lipid Efflux. Biochemistry. PMID 26506427 DOI: 10.1021/acs.biochem.5b00894  0.305
2015 Tiniakou I, Kanaki Z, Georgopoulos S, Chroni A, Van Eck M, Fotakis P, Zannis VI, Kardassis D. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice. Atherosclerosis. 243: 77-85. PMID 26363436 DOI: 10.1016/j.atherosclerosis.2015.08.028  0.783
2015 Dafnis I, Metso J, Zannis VI, Jauhiainen M, Chroni A. Influence of Isoforms and Carboxyl-Terminal Truncations on the Capacity of Apolipoprotein E To Associate with and Activate Phospholipid Transfer Protein. Biochemistry. 54: 5856-66. PMID 26337529 DOI: 10.1021/acs.biochem.5b00681  0.368
2015 Fotakis P, Kuivenhoven JA, Dafnis E, Kardassis D, Zannis VI. The Effect of Natural LCAT Mutations on the Biogenesis of HDL. Biochemistry. 54: 3348-59. PMID 25948084 DOI: 10.1021/acs.biochem.5b00180  0.804
2015 Tiniakou I, Drakos E, Sinatkas V, Van Eck M, Zannis VI, Boumpas D, Verginis P, Kardassis D. High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function. Journal of Immunology (Baltimore, Md. : 1950). 194: 4676-87. PMID 25870241 DOI: 10.4049/Jimmunol.1402870  0.779
2015 Kardassis D, Gafencu A, Zannis VI, Davalos A. Regulation of HDL genes: transcriptional, posttranscriptional, and posttranslational. Handbook of Experimental Pharmacology. 224: 113-79. PMID 25522987 DOI: 10.1007/978-3-319-09665-0_3  0.798
2015 Zannis VI, Fotakis P, Koukos G, Kardassis D, Ehnholm C, Jauhiainen M, Chroni A. HDL biogenesis, remodeling, and catabolism. Handbook of Experimental Pharmacology. 224: 53-111. PMID 25522986 DOI: 10.1007/978-3-319-09665-0_2  0.806
2015 Hasballa R, Rohrer L, Fotakis P, Zannis V, Parks J, Eckardstein Av. Characterization of APOA-I and HDL metabolism in an endothelial specific ABCA1 deficient mouse model Atherosclerosis. 241. DOI: 10.1016/J.Atherosclerosis.2015.04.153  0.509
2014 Fotakis P, Vezeridis A, Dafnis I, Chroni A, Kardassis D, Zannis VI. apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL. Journal of Lipid Research. 55: 1310-1323. PMID 24776540 DOI: 10.1194/Jlr.M048348  0.833
2014 Daniil G, Zannis VI, Chroni A. Correction: Effect of apoA-I mutations in the capacity of reconstituted HDL to promote ABCG1-mediated cholesterol efflux Plos One. 9. DOI: 10.1371/journal.pone.0108141  0.391
2014 Tiniakou I, Zannis VI, Boumpas D, Verginis P, Kardassis D. A8.28 Reconstituted high density lipoprotein (RHDL) modulates TH1 and TH17 immune responses and pro-inflammatory cytokine production in a murine model of rheumatoid arthritis Annals of the Rheumatic Diseases. 73. DOI: 10.1136/Annrheumdis-2013-205124.202  0.345
2014 Hasballa R, Rohrer L, Fotakis P, Zannis V, Parks J, von Eckardstein A. Lipoprotein metabolism and transendothelial apolipoprotein a-i transport in mice with an endothelium specific knock-out of ATP binding cassette transporter a1 Atherosclerosis. 235: e21. DOI: 10.1016/J.Atherosclerosis.2014.05.029  0.362
2013 Fotakis P, Tiniakou I, Kateifides AK, Gkolfinopoulou C, Chroni A, Stratikos E, Zannis VI, Kardassis D. Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL. Journal of Lipid Research. 54: 3293-302. PMID 24123812 DOI: 10.1194/jlr.M043489  0.818
2013 Fotakis P, Kateifides AK, Gkolfinopoulou C, Georgiadou D, Beck M, Gründler K, Chroni A, Stratikos E, Kardassis D, Zannis VI. Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDL. Journal of Lipid Research. 54: 3281-92. PMID 23990662 DOI: 10.1194/jlr.M038356  0.803
2013 Daniil G, Zannis VI, Chroni A. Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux. Plos One. 8: e67993. PMID 23826352 DOI: 10.1371/Journal.Pone.0067993  0.558
2013 Georgiadou D, Chroni A, Drosatos K, Kypreos KE, Zannis VI, Stratikos E. Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles. Atherosclerosis. 226: 385-91. PMID 23228878 DOI: 10.1016/J.Atherosclerosis.2012.11.013  0.742
2013 Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L, Stratikos E, Kardassis D, Zannis VI. ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT. Journal of Lipid Research. 54: 107-15. PMID 23132909 DOI: 10.1194/jlr.M030114  0.813
2013 Tiniakou I, Zannis V, Boumpas D, Verginis P, Kardassis D. A3.15 Reconstituted High Density Lipoprotein (rHDL) Modulates T Effector Cell Function in a Murine Model of Rheumatoid Arthritis Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-203216.15  0.382
2012 Lampropoulou A, Zannis VI, Kypreos KE. Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological properties. Biochemical Pharmacology. 84: 1451-8. PMID 22985620 DOI: 10.1016/J.Bcp.2012.09.006  0.524
2012 Koupenova M, Johnston-Cox H, Vezeridis A, Gavras H, Yang D, Zannis V, Ravid K. A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation. 125: 354-63. PMID 22144568 DOI: 10.1161/Circulationaha.111.057596  0.709
2011 Georgiadou D, Chroni A, Vezeridis A, Zannis VI, Stratikos E. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia. Plos One. 6: e27037. PMID 22069485 DOI: 10.1371/Journal.Pone.0027037  0.802
2011 Biedzka-Sarek M, Metso J, Kateifides A, Meri T, Jokiranta TS, Muszyński A, Radziejewska-Lebrecht J, Zannis V, Skurnik M, Jauhiainen M. Apolipoprotein A-I exerts bactericidal activity against Yersinia enterocolitica serotype O:3. The Journal of Biological Chemistry. 286: 38211-9. PMID 21896489 DOI: 10.1074/Jbc.M111.249482  0.395
2011 Drosatos K, Drosatos-Tampakaki Z, Khan R, Homma S, Schulze PC, Zannis VI, Goldberg IJ. Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction. The Journal of Biological Chemistry. 286: 36331-9. PMID 21873422 DOI: 10.1074/Jbc.M111.272146  0.725
2011 Vezeridis AM, Chroni A, Zannis VI. Domains of apoE4 required for the biogenesis of apoE-containing HDL. Annals of Medicine. 43: 302-11. PMID 21604997 DOI: 10.3109/07853890.2010.549143  0.813
2011 Kateifides AK, Gorshkova IN, Duka A, Chroni A, Kardassis D, Zannis VI. Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL. Journal of Lipid Research. 52: 1363-72. PMID 21504968 DOI: 10.1194/jlr.M012989  0.815
2011 Haase CL, Frikke-Schmidt R, Nordestgaard BG, Kateifides AK, Kardassis D, Nielsen LB, Andersen CB, Køber L, Johnsen AH, Grande P, Zannis VI, Tybjaerg-Hansen A. Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. Journal of Internal Medicine. 270: 136-46. PMID 21443680 DOI: 10.1111/j.1365-2796.2011.02381.x  0.303
2011 Ohnsorg PM, Rohrer L, Perisa D, Kateifides A, Chroni A, Kardassis D, Zannis VI, von Eckardstein A. Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells. The Journal of Biological Chemistry. 286: 7744-54. PMID 21209084 DOI: 10.1074/Jbc.M110.193524  0.787
2011 Vezeridis AM, Drosatos K, Zannis VI. Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4. Journal of Lipid Research. 52: 45-56. PMID 20861163 DOI: 10.1194/Jlr.M008409  0.845
2010 Mosialou I, Zannis VI, Kardassis D. Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. The Journal of Biological Chemistry. 285: 30719-30. PMID 20660599 DOI: 10.1074/Jbc.M110.131771  0.779
2010 Dafnis I, Stratikos E, Tzinia A, Tsilibary EC, Zannis VI, Chroni A. An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42. Journal of Neurochemistry. 115: 873-84. PMID 20412390 DOI: 10.1111/J.1471-4159.2010.06756.X  0.322
2010 Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. Journal of Lipid Research. 51: 1513-23. PMID 20124555 DOI: 10.1194/Jlr.M004812  0.714
2010 Sanoudou D, Duka A, Drosatos K, Hayes KC, Zannis VI. Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice Pharmacogenomics Journal. 10: 165-179. PMID 19949424 DOI: 10.1038/Tpj.2009.51  0.516
2009 Zannis V, Drosatos K, Kypreos K, Vezeridis A, Chroni A. Abstract: 1498 THE ROLE OF APOLIPOPROTEIN E IN TRIGLYCERIDE HOMEOSTASIS AND THE BIOGENESIS OF HDL Atherosclerosis Supplements. 10: e190. DOI: 10.1016/S1567-5688(09)70195-3  0.748
2009 Sanoudou D, Drosatos K, Duka A, Tserga A, Hayes KC, Zannis VI. Esrrg participates in the fibrate mediated activation of genes of lipid and lipo-protein metabolism in a human apoA-I transgenic mouse model: A pharmacogenomics approach Epitheorese Klinikes Farmakologias Kai Farmakokinetikes. 27: 92-94.  0.397
2008 Gorshkova IN, Kypreos KE, Gantz DL, Zannis VI, Atkinson D. Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia. Biochemistry. 47: 12644-54. PMID 18959431 DOI: 10.1021/Bi8015857  0.479
2008 Chroni A, Pyrpassopoulos S, Thanassoulas A, Nounesis G, Zannis VI, Stratikos E. Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Biochemistry. 47: 9071-80. PMID 18690708 DOI: 10.1021/Bi800469R  0.338
2008 Zannis VI, Koukos G, Drosatos K, Vezeridis A, Zanni EE, Kypreos KE, Chroni A. Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Annals of Medicine. 40: 14-28. PMID 18246469 DOI: 10.1080/07853890701687219  0.846
2008 Nieland TJ, Shaw JT, Jaipuri FA, Duffner JL, Koehler AN, Banakos S, Zannis VI, Kirchhausen T, Krieger M. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. Biochemistry. 47: 460-72. PMID 18067275 DOI: 10.1021/Bi701277X  0.436
2008 Kardassis D, Drosatos C, Zannis VI. Regulation of Genes Involved in the Biogenesis and the Remodeling of HDL High-Density Lipoproteins: From Basic Biology to Clinical Aspects. 235-265. DOI: 10.1002/9783527625178.ch10  0.313
2007 Thymiakou E, Zannis VI, Kardassis D. Physical and functional interactions between liver X receptor/retinoid X receptor and Sp1 modulate the transcriptional induction of the human ATP binding cassette transporter A1 gene by oxysterols and retinoids. Biochemistry. 46: 11473-83. PMID 17887732 DOI: 10.1021/Bi700994M  0.791
2007 Koukos G, Chroni A, Duka A, Kardassis D, Zannis VI. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. Biochemistry. 46: 10713-21. PMID 17711302 DOI: 10.1021/Bi7003203  0.826
2007 Drosatos K, Kypreos KE, Zannis VI. Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein. Biochemistry. 46: 9645-53. PMID 17655277 DOI: 10.1021/Bi700232G  0.784
2007 Gafencu AV, Robciuc MR, Fuior E, Zannis VI, Kardassis D, Simionescu M. Inflammatory signaling pathways regulating ApoE gene expression in macrophages. The Journal of Biological Chemistry. 282: 21776-85. PMID 17553793 DOI: 10.1074/Jbc.M611422200  0.77
2007 Koukos G, Chroni A, Duka A, Kardassis D, Zannis VI. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT. The Biochemical Journal. 406: 167-74. PMID 17506726 DOI: 10.1042/Bj20070296  0.828
2007 Drosatos K, Sanoudou D, Kypreos KE, Kardassis D, Zannis VI. A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. The Journal of Biological Chemistry. 282: 19556-64. PMID 17456467 DOI: 10.1074/Jbc.M700986200  0.823
2007 Chroni A, Koukos G, Duka A, Zannis VI. The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo. Biochemistry. 46: 5697-708. PMID 17447731 DOI: 10.1021/Bi602354T  0.566
2007 Kypreos KE, Zannis VI. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. The Biochemical Journal. 403: 359-67. PMID 17206937 DOI: 10.1042/Bj20061048  0.548
2006 Singaraja RR, Visscher H, James ER, Chroni A, Coutinho JM, Brunham LR, Kang MH, Zannis VI, Chimini G, Hayden MR. Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circulation Research. 99: 389-97. PMID 16873719 DOI: 10.1161/01.Res.0000237920.70451.Ad  0.44
2006 Nikolaidou-Neokosmidou V, Zannis VI, Kardassis D. Inhibition of hepatocyte nuclear factor 4 transcriptional activity by the nuclear factor kappaB pathway. The Biochemical Journal. 398: 439-50. PMID 16771709 DOI: 10.1042/BJ20060169  0.742
2006 Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. Journal of Molecular Medicine (Berlin, Germany). 84: 276-94. PMID 16501936 DOI: 10.1007/S00109-005-0030-4  0.547
2006 Gorshkova IN, Liu T, Kan HY, Chroni A, Zannis VI, Atkinson D. Structure and stability of apolipoprotein a-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation. Biochemistry. 45: 1242-54. PMID 16430220 DOI: 10.1021/Bi051669R  0.434
2006 Kypreos KE, Zannis VI. LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. Journal of Lipid Research. 47: 521-9. PMID 16339113 DOI: 10.1194/Jlr.M500322-Jlr200  0.512
2006 Zannis V, Kypreos K. Mo-W15:8 Novel pathway of biogenesis of apoe-containing HDL with the participation of ABCA1 and LCAT: Implications for dyslipidemias and atherogenesis Atherosclerosis Supplements. 7: 39. DOI: 10.1016/S1567-5688(06)80124-8  0.34
2005 Chroni A, Duka A, Kan HY, Liu T, Zannis VI. Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency. Biochemistry. 44: 14353-66. PMID 16245952 DOI: 10.1021/Bi050962O  0.534
2005 Chroni A, Nieland TJ, Kypreos KE, Krieger M, Zannis VI. SR-BI mediates cholesterol efflux via its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry. 44: 13132-43. PMID 16185081 DOI: 10.1021/Bi051029O  0.574
2005 Gerritsen G, Rensen PC, Kypreos KE, Zannis VI, Havekes LM, Willems van Dijk K. ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression. Journal of Lipid Research. 46: 1466-73. PMID 15863838 DOI: 10.1194/Jlr.M400479-Jlr200  0.481
2005 Chroni A, Kan HY, Shkodrani A, Liu T, Zannis VI. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice. Biochemistry. 44: 4108-17. PMID 15751988 DOI: 10.1021/Bi047998L  0.588
2005 Kypreos KE, van Dijk KW, Havekes LM, Zannis VI. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia. The Journal of Biological Chemistry. 280: 6276-84. PMID 15576362 DOI: 10.1074/Jbc.M413458200  0.573
2004 Chroni A, Kan HY, Kypreos KE, Gorshkova IN, Shkodrani A, Zannis VI. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice. Biochemistry. 43: 10442-57. PMID 15301543 DOI: 10.1021/Bi049782P  0.601
2004 Kan HY, Georgopoulos S, Zanni M, Shkodrani A, Tzatsos A, Xie HX, Zannis VI. Contribution of the hormone-response elements of the proximal ApoA-I promoter, ApoCIII enhancer, and C/EBP binding site of the proximal ApoA-I promoter to the hepatic and intestinal expression of the ApoA-I and ApoCIII genes in transgenic mice. Biochemistry. 43: 5084-93. PMID 15109267 DOI: 10.1021/Bi035764G  0.399
2004 Nieland TJ, Chroni A, Fitzgerald ML, Maliga Z, Zannis VI, Kirchhausen T, Krieger M. Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide. Journal of Lipid Research. 45: 1256-65. PMID 15102890 DOI: 10.1194/Jlr.M300358-Jlr200  0.493
2004 Zannis VI, Chroni A, Kypreos KE, Kan HY, Cesar TB, Zanni EE, Kardassis D. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Current Opinion in Lipidology. 15: 151-66. PMID 15017358 DOI: 10.1097/00041433-200404000-00008  0.764
2004 Chroni A, Liu T, Fitzgerald ML, Freeman MW, Zannis VI. Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1. Biochemistry. 43: 2126-39. PMID 14967052 DOI: 10.1021/Bi035813P  0.443
2004 Fitzgerald ML, Morris AL, Chroni A, Mendez AJ, Zannis VI, Freeman MW. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. Journal of Lipid Research. 45: 287-94. PMID 14617740 DOI: 10.1194/Jlr.M300355-Jlr200  0.488
2003 Hatzivassiliou E, Koukos G, Ribeiro A, Zannis V, Kardassis D. Functional specificity of two hormone response elements present on the human apoA-II promoter that bind retinoid X receptor alpha/thyroid receptor beta heterodimers for retinoids and thyroids: synergistic interactions between thyroid receptor beta and upstream stimulatory factor 2a. The Biochemical Journal. 376: 423-31. PMID 12959642 DOI: 10.1042/Bj20030549  0.738
2003 Li X, Kypreos K, Zanni EE, Zannis V. Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain. Biochemistry. 42: 10406-17. PMID 12950167 DOI: 10.1021/Bi027093C  0.45
2003 Kypreos KE, Li X, van Dijk KW, Havekes LM, Zannis VI. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry. 42: 9841-53. PMID 12924933 DOI: 10.1021/Bi0271796  0.511
2003 Zannis VI, Liu T, Zanni M, Kan HY, Kardassis D. Regulatory gene mutations affecting apolipoprotein gene expression: functions and regulatory behavior of known genes may guide future pharmacogenomic approaches to therapy. Clinical Chemistry and Laboratory Medicine. 41: 411-24. PMID 12747582 DOI: 10.1515/Cclm.2003.064  0.764
2003 Chou WC, Prokova V, Shiraishi K, Valcourt U, Moustakas A, Hadzopoulou-Cladaras M, Zannis VI, Kardassis D. Mechanism of a transcriptional cross talk between transforming growth factor-beta-regulated Smad3 and Smad4 proteins and orphan nuclear receptor hepatocyte nuclear factor-4. Molecular Biology of the Cell. 14: 1279-94. PMID 12631740 DOI: 10.1091/mbc.E02-07-0375  0.738
2003 Kardassis D, Roussou A, Papakosta P, Boulias K, Talianidis I, Zannis VI. Synergism between nuclear receptors bound to specific hormone response elements of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene regulation by bile acids and retinoids. The Biochemical Journal. 372: 291-304. PMID 12585964 DOI: 10.1042/BJ20021532  0.739
2003 Gerritsen G, Kypreos KE, van der Zee A, Teusink B, Zannis VI, Havekes LM, van Dijk KW. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain. Journal of Lipid Research. 44: 408-14. PMID 12576523 DOI: 10.1194/Jlr.M200313-Jlr200  0.485
2003 Chroni A, Liu T, Gorshkova I, Kan HY, Uehara Y, Von Eckardstein A, Zannis VI. The central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type ApoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. The Journal of Biological Chemistry. 278: 6719-30. PMID 12488454 DOI: 10.1074/Jbc.M205232200  0.562
2002 Gorshkova IN, Liu T, Zannis VI, Atkinson D. Lipid-free structure and stability of apolipoprotein A-I: probing the central region by mutation. Biochemistry. 41: 10529-39. PMID 12173940 DOI: 10.1021/Bi025807D  0.394
2002 Georgopoulos S, McKee A, Kan HY, Zannis VI. Generation and characterization of two transgenic mouse lines expressing human ApoE2 in neurons and glial cells Biochemistry. 41: 9293-9301. PMID 12135350 DOI: 10.1021/Bi015971L  0.386
2002 Liu T, Krieger M, Kan HY, Zannis VI. The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. The Journal of Biological Chemistry. 277: 21576-84. PMID 11882653 DOI: 10.1074/Jbc.M112103200  0.506
2002 Li X, Kan HY, Lavrentiadou S, Krieger M, Zannis V. Reconstituted discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1-165 domain of ApoE suffices for receptor binding. The Journal of Biological Chemistry. 277: 21149-57. PMID 11861652 DOI: 10.1074/Jbc.M200658200  0.492
2002 Kardassis D, Falvey E, Tsantili P, Hadzopoulou-Cladaras M, Zannis V. Direct physical interactions between HNF-4 and Sp1 mediate synergistic transactivation of the apolipoprotein CIII promoter. Biochemistry. 41: 1217-1228. PMID 11802721 DOI: 10.1021/Bi015618F  0.752
2001 Reardon CA, Kan HY, Cabana V, Blachowicz L, Lukens JR, Wu Q, Liadaki K, Getz GS, Zannis VI. In vivo studies of HDL assembly and metabolism using adenovirus-mediated transfer of apoA-I mutants in apoA-I-deficient mice Biochemistry. 40: 13670-13680. PMID 11695916 DOI: 10.1021/Bi011451E  0.546
2001 Kypreos KE, Teusink B, Van Dijk KW, Havekes LM, Zannis VI. Analysis of the structure and function relationship of the human apolipoprotein E in vivo, using adenovirus-mediated gene transfer The Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 15: 1598-1600. PMID 11427498 DOI: 10.1096/Fj.00-0882Fje  0.564
2001 Kypreos KE, Morani P, Van Dijk KW, Havekes LM, Zannis VI. The amino-terminal 1-185 domain of apoe promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoe-deficient mice Biochemistry. 40: 6027-6035. PMID 11352738 DOI: 10.1021/Bi002414A  0.539
2001 Zannis VI, Kan HY, Kritis A, Zanni EE, Kardassis D. Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo Current Opinion in Lipidology. 12: 181-207. PMID 11264990 DOI: 10.1097/00041433-200104000-00012  0.361
2001 Zannis VI, Kan HY, Kritis A, Zanni E, Kardassis D. Transcriptional regulation of the human apolipoprotein genes Frontiers in Bioscience : a Journal and Virtual Library. 6. PMID 11229886 DOI: 10.1007/978-1-4684-5904-3_1  0.429
2001 Cohen JC, Zannis VI. Genes affecting atherosclerosis Current Opinion in Lipidology. 12: 93-95. DOI: 10.1097/00041433-200104000-00001  0.313
2001 Kypreos KE, Van Dijk KW, Van Der Zee A, Havekes LM, Zannis VI. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion Journal of Biological Chemistry. 276: 19778-19786. DOI: 10.1074/Jbc.M100418200  0.563
2000 Segrest JP, Harvey SC, Zannis V. Detailed molecular model of apolipoprotein A-I on the surface of high-density lipoproteins and its functional implications. Trends in Cardiovascular Medicine. 10: 246-52. PMID 11282302 DOI: 10.1016/S1050-1738(00)00078-5  0.448
2000 Gorshkova IN, Liadaki K, Gursky O, Atkinson D, Zannis VI. Probing the lipid-free structure and stability of apolipoprotein A-I by mutation Biochemistry. 39: 15910-15919. PMID 11123918 DOI: 10.1021/Bi0014406  0.355
2000 Georgopoulos S, Kan H, Reardon-Alulis C, Zannis V. The SP1 sites of the human apoCIII enhancer are essential for the expression of the apoCIII gene and contribute to the hepatic and intestinal expression of the apoA-I gene in transgenic mice Nucleic Acids Research. 28: 4919-4929. PMID 11121483 DOI: 10.1093/Nar/28.24.4919  0.391
2000 Carraway M, Herscovitz H, Zannis V, Small DM. Specificity of lipid incorporation is determined by sequences in the N-terminal 37 of apoB. Biochemistry. 39: 9737-45. PMID 10933790 DOI: 10.1021/Bi000791H  0.393
2000 Kan H, Georgopoulos S, Zannis VI. A Hormone Response Element in the Human Apolipoprotein CIII (ApoCIII) Enhancer Is Essential for Intestinal Expression of the ApoA-I and ApoCIII Genes and Contributes to the Hepatic Expression of the Two Linked Genes in Transgenic Mice Journal of Biological Chemistry. 275: 30423-30431. PMID 10893424 DOI: 10.1074/Jbc.M005641200  0.38
2000 Liadaki KN, Liu T, Xu S, Ishida BY, Duchateaux PN, Krieger JP, Kane J, Krieger M, Zannis VI. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. The Journal of Biological Chemistry. 275: 21262-71. PMID 10801839 DOI: 10.1074/jbc.M002310200  0.397
2000 Segrest JP, Li L, Anantharamaiah GM, Harvey SC, Liadaki KN, Zannis V. Structure and function of apolipoprotein A-I and high-density lipoprotein. Current Opinion in Lipidology. 11: 105-15. PMID 10787171 DOI: 10.1097/00041433-200004000-00002  0.455
2000 Zannis VI, Cohen J. Old and new players in the lipoprotein system Current Opinion in Lipidology. 11: 101-103. PMID 10787170 DOI: 10.1097/00041433-200004000-00001  0.353
2000 Willems van Dijk K, Kypreos K, van der Zee A, Zannis V, Havekes L. apoE-induced hypertriglyceridemia is modulated by deleting the carboxy-terminal region of the apoE molecule Atherosclerosis. 151: 174-175. DOI: 10.1016/S0021-9150(00)80792-3  0.362
1999 Aleshkov SB, Li X, Lavrentiadou SN, Zannis VI. Contribution of cysteine 158, the glycosylation site theonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide β (1-40) Biochemistry. 38: 8918-8925. PMID 10413465 DOI: 10.1021/Bi982002Q  0.401
1999 Pissios P, Kan HY, Nagaoka S, Zannis VI. SREBP-1 binds to multiple sites and transactivates the human Apoa-II promoter in vitro: SREBP-1 mutants defective in DNA binding or transcriptional activation repress Apoa-II promoter activity Arteriosclerosis, Thrombosis, and Vascular Biology. 19: 1456-1469. PMID 10364076 DOI: 10.1161/01.Atv.19.6.1456  0.412
1999 Le Beyec J, Chauffeton V, Kan HY, Janvier PL, Cywiner-Golenzer C, Chatelet FP, Kalopissis AD, Zannis V, Chambaz J, Pinçon-Raymond M, Cardot P. The -700/-310 fragment of the apolipoprotein A-IV gene combined with the -890/-500 apolipoprotein C-III enhancer is sufficient to direct a pattern of gene expression similar to that for the endogenous apolipoprotein A-IV gene. The Journal of Biological Chemistry. 274: 4954-61. PMID 9988739 DOI: 10.1074/Jbc.274.8.4954  0.365
1999 Kan HY, Pissios P, Chambaz J, Zannis VI. DNA binding specificity and transactivation properties of SREBP-2 bound to multiple sites on the human apoA-II promoter Nucleic Acids Research. 27: 1104-1117. PMID 9927745 DOI: 10.1093/Nar/27.4.1104  0.369
1999 Lavrentiadou SN, Hadzopoulou-Cladaras M, Kardassis D, Zannis VI. Binding specificity and modulation of the human apocIII promoter activity by heterodimers of ligand-dependent nuclear receptors Biochemistry. 38: 964-975. PMID 9893992 DOI: 10.1021/Bi981068I  0.376
1999 Kan H, Georgopoulos S, Zanni E, Zannis V. Probing the in vivo regulation and tissue specific expression of the apoA-1 and apoCIII gene cluster in transgenic mice Atherosclerosis. 144: 164. DOI: 10.1016/S0021-9150(99)80626-1  0.33
1998 Hadzopoulou-Cladaras M, Lavrentiadou SN, Zannis VI, Kardassis D. Transactivation of the ApoCIII promoter by ATF-2 and repression by members of the Jun family Biochemistry. 37: 14078-14087. PMID 9760243 DOI: 10.1021/Bi9804176  0.385
1997 Aleshkov S, Abraham CR, Zannis VI. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry. 36: 10571-80. PMID 9265639 DOI: 10.1021/Bi9626362  0.339
1997 Xu S, Laccotripe M, Huang X, Rigotti A, Zannis VI, Krieger M. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake Journal of Lipid Research. 38: 1289-1298. PMID 9254056  0.424
1997 Laccotripe M, Makrides SC, Jonas A, Zannis VI. The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein Journal of Biological Chemistry. 272: 17511-17522. PMID 9211897 DOI: 10.1074/Jbc.272.28.17511  0.501
1997 Laccotripe M, Zanni E, Makrides S, Jonas A, Zannis V. 1.P.12 Hydrophobic residues between aminoacids 211–229 of apoA-I play an important role in binding to lipids and lipoproteins Atherosclerosis. 134: 19. DOI: 10.1016/S0021-9150(97)88193-2  0.417
1996 Tzameli I, Zannis VI. Binding specificity and modulation of the ApoA-I promoter activity by homo- and heterodimers of nuclear receptors Journal of Biological Chemistry. 271: 8402-8415. PMID 8626539 DOI: 10.1074/Jbc.271.14.8402  0.397
1995 Herscovitz H, Kritis A, Talianidis I, Zanni E, Zannis V, Small DM. Murine mammary-derived cells secrete the N-terminal 41% of human apolipoprotein B on high density lipoprotein-sized lipoproteins containing a triacylglycerol-rich core Proceedings of the National Academy of Sciences of the United States of America. 92: 659-663. PMID 7846033 DOI: 10.1073/Pnas.92.3.659  0.447
1995 Talianidis I, Tambakaki A, Toursounova J, Zannis VI. Complex interactions between SP1 bound to multiple distal regulatory sites and HNF-4 bound to the proximal promoter lead to transcriptional activation of liver-specific human APOCIII gene Biochemistry. 34: 10298-10309. PMID 7640286 DOI: 10.1021/Bi00032A025  0.371
1994 Lopez J, Roghani A, Bertrand J, Zanni E, Kalopissis A, Zannis VI, Chambaz J. Intracellular early and late modifications of human apolipoprotein A-II. Effect of glutamine-+1 to leucine substitution Biochemistry. 33: 4056-4064. PMID 8142408 DOI: 10.1021/Bi00179A034  0.321
1994 Ktistaki E, Lacorte Jm, Katrakili N, Zannis VI, Talianidis I. Transcriptional regulation of the apolipoprotein A-IV gene involves synergism between a proximal orphan receptor response element and a distant enhancer located in the upstream promoter region of the apolipoprotein C-III gene Nucleic Acids Research. 22: 4689-4696. PMID 7984419 DOI: 10.1093/nar/22.22.4689  0.324
1994 Cardot P, Pastier D, Lacorte JM, Mangeney M, Zannis VI, Chambaz J. Purification and characterization of nuclear factors binding to the negative regulatory element D of human apolipoprotein A-II promoter: A negative regulatory effect is reversed by GABP, an Ets-related protein Biochemistry. 33: 12139-12148. PMID 7918435 DOI: 10.1021/Bi00206A017  0.355
1994 Zannis V, Kardassis D, Ktistaki E, Tambakaki N, Tzameli E, Cladaras C, Talianidis I. Transcriptional regulation of the genes involved in lipoprotein metabolism Atherosclerosis. 109: 172. DOI: 10.1016/0021-9150(94)93695-1  0.392
1993 Zannis VI, Kardassis D, Zanni EE. Genetic mutations affecting human lipoproteins, their receptors, and their enzymes Advances in Human Genetics. 21: 145-320. PMID 8391199 DOI: 10.1007/978-1-4615-3010-7_3  0.329
1993 Cardot P, Chambaz J, Kardassis D, Cladaras C, Zannis VI. Factors participating in the liver-specific expression of the human apolipoprotein A-II gene and their significance for transcription Biochemistry. 32: 9080-9093. PMID 8369280 DOI: 10.1021/Bi00086A013  0.377
1992 Minnich A, Collet X, Roghani A, Cladaras C, Hamilton RL, Fielding CJ, Zannis VI. Site-directed mutagenesis and structure-function analysis of the human apolipoprotein A-I. Relation between lecithin-cholesterol acyltransferase activation and lipid binding. The Journal of Biological Chemistry. 267: 16553-60. PMID 1644835  0.422
1992 Herscovitz H, Gantz D, Tercyak AM, Zannis VI, Small DM. Expression of human apolipoprotein E but not that of apolipoprotein A-I by mouse C127 cells is associated with increased secretion of lipids in the form of vesicles and discs Journal of Lipid Research. 33: 791-803. PMID 1512507  0.372
1992 Zannis VI, Kardassis D, Cardot P, Hadzopoulou-Cladaras M, Zanni EE, Cladaras C. Molecular biology of the human apolipoprotein genes: Gene regulation and structure/function relationship Current Opinion in Lipidology. 3: 96-113. DOI: 10.1097/00041433-199204000-00006  0.32
1991 Lenich CM, Chobanian AV, Brecher P, Zannis VI. Effect of dietary cholesterol and alloxan-diabetes on tissue cholesterol and apolipoprotein E mRNA levels in the rabbit Journal of Lipid Research. 32: 431-438. PMID 2066673  0.323
1991 Hussain MM, Roghani A, Cladaras C, Zanni EE, Zannis VI. Secretion of lipid-poor nascent human apolipoprotein apoAI, apoCIII, and apoE by cell clones expressing the corresponding genes Electrophoresis. 12: 273-283. PMID 1906400 DOI: 10.1002/Elps.1150120408  0.515
1991 Herscovitz H, Hadzopoulou-Cladaras M, Walsh MT, Cladaras C, Zannis VI, Small DM. Expression, secretion, and lipid-binding characterization of the N-terminal 17% of apolipoprotein B Proceedings of the National Academy of Sciences of the United States of America. 88: 7313-7317. PMID 1871138 DOI: 10.1073/Pnas.88.16.7313  0.427
1991 Zannis VI, Cladaras C, Zanni EE. Apolipoprotein and lipoprotein synthesis and modifications Current Opinion in Lipidology. 2: 149-155. DOI: 10.1097/00041433-199106000-00002  0.425
1990 Kardassis D, Hadzopoulou-Cladaras M, Ramji DP, Cortese R, Zannis VI, Cladaras C. Characterization of the Promoter Elements Required for Hepatic and Intestinal Transcription of the Human apoB Gene: Definition of the DNA-Binding Site of a Tissue-Specific Transcriptional Factor Molecular and Cellular Biology. 10: 2653-2659. PMID 2342459 DOI: 10.1128/Mcb.10.6.2653  0.348
1990 Bresnahan MR, Flordellis CS, Vassilatis DK, Makrides SC, Zannis VI, Gavras H. High level of expression of functional human platelet α2-adrenergic receptors in a stable mouse C127 cell line Bba - Molecular Cell Research. 1052: 439-445. PMID 1972337 DOI: 10.1016/0167-4889(90)90153-5  0.322
1990 Chambaz J, Pastier D, Bereziat G, Zannis V. Promoter elements involved in transcriptional regulation of human apolipoprotein AII gene Journal of Molecular and Cellular Cardiology. 22: S10. DOI: 10.1016/0022-2828(90)91975-D  0.357
1989 Hussain MM, Zanni EE, Kelly M, Zannis VI. Synthesis, modification, and flotation properties of rat hepatocyte apolipoproteins Biochimica Et Biophysica Acta - Lipids and Lipid Metabolism. 1001: 90-101. PMID 2912498 DOI: 10.1016/0005-2760(89)90311-1  0.489
1989 Zannis VI. Molecular biology of human apolipoproteins B and E and associated diseases of lipoprotein metabolism Advances in Lipid Research. 23: 1-64. PMID 2560890 DOI: 10.1016/B978-0-12-024923-7.50005-4  0.492
1988 Roghani A, Zannis VI. Alterations of the glutamine residues of human apolipoprotein AI propeptide by in vitro mutagenesis. Characterization of the normal and mutant protein forms Biochemistry. 27: 7428-7435. PMID 3207684 DOI: 10.1021/Bi00419A038  0.436
1988 Roghani A, Zannis VI. Mutagenesis of the glycosylation site of human apoCIII. O-linked glycosylation is not required for apoCIII secretion and lipid binding Journal of Biological Chemistry. 263: 17925-17932. PMID 3192519  0.337
1988 Makrides SC, Ruiz-Opazo N, Hayden M, Nussbaum AL, Breslow JL, Zannis VI. Sequence and expression of Tangier apoA-I gene European Journal of Biochemistry. 173: 465-471. PMID 3129297 DOI: 10.1111/J.1432-1033.1988.Tb14022.X  0.408
1988 Zannis VI, Hussain MM, Hadzopoulou-Cladaras M, Kouvatsi A, Kardassis D, Cladaras C. Molecular biology of human apolipoprotein B and related diseases Advances in Experimental Medicine and Biology. 243: 107-121. PMID 3066172 DOI: 10.1007/978-1-4613-0733-4_14  0.501
1986 Zanni EE, Stephan ZF, Zannis VI, Breslow JL, Hayes KC. ApoE distribution among lipoproteins of rhesus monkeys is modulated by dietary fat and cholesterol Journal of Nutrition. 116: 1611-1619. PMID 3761018  0.342
1986 Karathanasis SK, Yunis I, Zannis VI. Structure, evolution, and tissue-specific synthesis of human apolipoprotein AIV Biochemistry. 25: 3962-3970. PMID 3755616 DOI: 10.1021/Bi00361A034  0.346
1986 Zannis VI. Genetic polymorphism in human apolipoprotein E Methods in Enzymology. 823-851. PMID 3724530 DOI: 10.1016/0076-6879(86)28109-4  0.371
1986 Cladaras C, Hadzopoulou-Cladaras M, Nolte RT, Atkinson D, Zannis VI. The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms Embo Journal. 5: 3495-3507. PMID 3030729 DOI: 10.1002/J.1460-2075.1986.Tb04675.X  0.346
1986 Karathanasis SK, Zannis VI, Breslow JL. Characterization of the apolipoprotein A-I-C-III gene complex Methods in Enzymology. 712-726. PMID 3014271 DOI: 10.1016/0076-6879(86)28101-X  0.358
1986 Zannis VI, Karathanasis SK, Forbes GM, Breslow JL. [40] Intra- and extracellular modifications of apolipoproteins Methods in Enzymology. 128: 690-712. PMID 3014270 DOI: 10.1016/0076-6879(86)28100-8  0.362
1985 Zannis VI, Cole FS, Jackson CL, Kurnit DM, Karathanasis SK. Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages Biochemistry. 24: 4450-4455. PMID 3931677 DOI: 10.1021/Bi00337A028  0.376
1983 Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of the human apolipoprotein A-I gene Proceedings of the National Academy of Sciences of the United States of America. 80: 6147-6151. PMID 6413973 DOI: 10.1073/Pnas.80.20.6147  0.394
1983 Zannis VI, Karathanasis SK, Keutmann HT, Goldberger G, Breslow JL. Intracellular and extracellular processing of human apolipoprotein A-I: Secreted apolipoprotein A-I isoprotein 2 is a propeptide Proceedings of the National Academy of Sciences of the United States of America. 80: 2574-2578. PMID 6405383 DOI: 10.1073/Pnas.80.9.2574  0.413
1983 Karathanasis SK, Norum RA, Zannis VI, Breslow JL. An inherited polymorphism in the human apolipoprotein A-I gene locus related to the development of atherosclerosis Nature. 301: 718-720. PMID 6402711 DOI: 10.1038/301718a0  0.421
1983 Karathanasis SK, Zannis VI, Breslow JL. A DNA insertion in the apolipoprotein A-I gene of patients with premature atherosclerosis Nature. 305: 823-825. PMID 6314145 DOI: 10.1038/305823a0  0.314
1981 Zannis VI, Breslow JL, Sangiacomo TR, Aden DP, Knowles BB. Characterization of the major apolipoproteins secreted by two human hepatoma cell lines Biochemistry. 20: 7089-7096. PMID 6274388 DOI: 10.1021/Bi00528A006  0.362
1981 Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification Biochemistry. 20: 1033-1041. PMID 6260135 DOI: 10.1021/Bi00507A059  0.337
Show low-probability matches.